옵션 체인은 다양한 행사가격과 만기일에 대한 Applied Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Applied Therapeutics에 대한 시장 심리를 평가합니다..

Applied Therapeutics (NASDAQ:APLT) 주식, 옵션 체인

Applied Therapeutics

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics Inc

Earnings

Earnings Beats

Earnings Misses

News

Cummins Q4 2024 GAAP EPS $3.02, Sales $8.447B Beat $8.071B Estimate

Northland Capital Markets analyst Michael Latimore maintains Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) with a Market Perform and raises the price target from $38 to $80.

Price Target

Analyst Ratings

PLTR

Northland Capital Markets Maintains Market Perform on Palantir Technologies, Raises Price Target to $80

Rosenblatt analyst Hans Mosesmann maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and maintains $250 price target.

Rosenblatt Maintains Buy on Advanced Micro Devices, Maintains $250 Price Target

Hubbell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) reported quarterly earnings of $4.10 per share which beat the analyst consensus estimate of $4.02 by 1.99 percent. This is a 11.11 percent increase over earnings of $3.69 per share from the same period last year. The company reported quarterly sales of $1.33 billion which missed the analyst consensus estimate of $1.41 billion by 5.48 percent. This is a 0.89 percent decrease over sales of $1.35 billion the same period last year.

HUBB

Hubbell Q4 2024 Adj EPS $4.10 Beats $4.02 Estimate, Sales $1.33B Miss $1.41B Estimate

ATI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.61 by 29.51 percent. This is a 23.44 percent increase over earnings of $0.64 per share from the same period last year. The company reported quarterly sales of $1.20 billion which beat the analyst consensus estimate of $1.09 billion by 10.02 percent. This is a 12.78 percent increase over sales of $1.06 billion the same period last year.

ATI Q4 2024 Adj EPS $0.79 Beats $0.61 Estimate, Sales $1.20B Beat $1.09B Estimate

Simplify Asset Management launched the Simplify Currency Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOXY#NYSE">FOXY</a>), an <a href="https://www.benzinga.com/etfs">actively managed fund</a> designed to benefit from foreign exchange market dynamics. The launch on Tuesday comes as global currency volatility rises, driven by Trump's push to weaken the dollar and uncertainty around tariffs.
In an interview with Benzinga, Managing Director, Portfolio Manager, and Emerging Markets Specialist at Simplify, Christopher Getter said, &#8220;There really isn't anything available to investors in the space, so in some sense, our ability to be original with a distinct product that is not an expression on the dollar, per se—although there are a handful of single currency products out there—motivated us.&#8221;
Also Read: <a href="https://www.benzinga.com/25/02/43438809/teucrium-expands-etf-offerings-with-yields-for-you-strategy-a-etf">Teucrium Expands ETF Offerings with Yields For You Strategy A ETF</a>
The new ETF employs two strategies to generate returns with minimal dependence on equities or bonds. The first strategy is an Emerging Markets carry trade, utilizing eight currency pairs, each benchmarked against the U.S. dollar. The fund will hold &#8220;long&#8221; positions in the four currencies offering the highest interest rates while &#8220;shorting&#8221; the four with the lowest rates. This strategy seeks to profit from yield differentials and currency fluctuations.
The second strategy takes six different pairs of G10 currencies. It involves taking &#8220;long&#8221; positions in the three currencies exhibiting the strongest yield momentum increases, while &#8220;shorting&#8221; the three with the weakest. The strategy benefits from the mean-reverting nature of G10 currencies, potentially lowering overall risk by combining lesser-correlated approaches across different markets. &#8220;This approach, which we have refined through a number of iterations, provided the best alpha and return potential,&#8221; Getter added.
The backdrop of global currency fluctuations makes FOXY's launch particularly timely. &#8220;Beyond the direct targets of tariffs like Mexico and China, we think the EM currencies can do well against the USD, which should provide a boost to performance,&#8221; said Getter.
The ETF also accounts for heightened FX volatility driven by geopolitical tensions and trade policies, such as the fresh batch of tariffs. &#8220;Without getting too deep into the specifics, we can scale our exposures at both the individual currency level as well as at the overall portfolio level to either take advantage of volatility or to adopt more of a defensive posture,&#8221; said Getter.
Amid policy uncertainty and geopolitical shifts, actively managed currency strategies like FOXY could offer investors an alternative way to diversify and hedge against volatile FX markets. &#8220;Correlations across traditional asset classes (think of a typical 60/40 mix) have risen, so we think there is a demand for uncorrelated asset classes and that this demand is becoming increasingly structural in nature,&#8221; Getter said.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43440361/exclusive-dogecoin-etf-justified-more-meme-coins-etfs-possible-bitwise-cio-says">EXCLUSIVE: Dogecoin ETF Justified, More Meme Coins ETFs Possible, Bitwise CIO Says</a></li>
</ul>
Photo: Shutterstock

New ETFs

Interview

ETFs

Simplify Exchange Traded Funds Simplify Currency Strategy ETF

FOXY

Simplify Launches FOXY ETF To Navigate FX Volatility, Tariff Uncertainty

Archer-Daniels Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) reported quarterly earnings of $1.14 per share which missed the analyst consensus estimate of $1.15 by 0.87 percent. This is a 16.18 percent decrease over earnings of $1.36 per share from the same period last year. The company reported quarterly sales of $21.50 billion which missed the analyst consensus estimate of $22.66 billion by 5.13 percent. This is a 6.44 percent decrease over sales of $22.98 billion the same period last year.

Archer-Daniels Midland Q4 2024 Adj EPS $1.14 Misses $1.15 Estimate, Sales $21.50B Miss $22.66B Estimate

The Trump (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>) meme coin has plunged 42.6% in the past week, following Donald Trump's tariff announcement—a sharp reversal for the <a href="https://www.benzinga.com/money/trump-coin-price-prediction">high-flying meme crypto</a>.
What Happened: According to Lookonchain, a whale who had pocketed $11.8 million in TRUMP gains in mid-January reinvested his profits, only to see the trade turn against him. 
The whale spent $33.9 million to acquire 766,083 TRUMP at an average price of $44.25, only to suffer a $21 million loss as prices collapsed. 
This move <a href="https://x.com/lookonchain/status/1886704116652810567">erased</a> not only their entire profit but also $9 million of the original capital.
Despite this steep drop, data from Merkle Science and Chainalysis, cited by Reuters, shows TRUMP having generated $100 million in trading fees in less than two weeks, highlighting continued high-volume activity.
Once the best-performing meme coin before the tariff news, TRUMP has now lost nearly 50% of its total valuation in just days.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43430801/exclusive-anthony-scaramucci-warns-donald-trumps-crypto-promises-may-be-a-mirage">EXCLUSIVE: Anthony Scaramucci Warns Donald Trump&#8217;s Crypto Promises May Be A &#8216;Mirage&#8217;</a>
What's Next: Trader Johnny believes buying TRUMP under $20 will be seen as a bargain in the coming months, predicting that it will ultimately reach new all-time highs.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I think buying <a href="https://twitter.com/search?q=%24TRUMP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TRUMP</a> sub $20 will be looked as a steal a few months from now Expecting this to go to new ATH&#39;s at some point <a href="https://t.co/6DDkqvUoUf">pic.twitter.com/6DDkqvUoUf</a>
&mdash; Johnny (@CryptoGodJohn) <a href="https://twitter.com/CryptoGodJohn/status/1886434777340739764?ref_src=twsrc%5Etfw">February 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Rodney, another crypto trader, <a href="https://x.com/cryptojourneyrs/status/1886425944942113031">notes</a> that despite the crash, TRUMP still holds the fourth position among meme coins, urging investors to stay patient for a recovery.
Trader Viktor <a href="https://x.com/thedefivillain/status/1886712178654503130">argues</a> that while the TRUMP and MELANIA meme coins were attractive short hedges, the risk/reward dynamics have now shifted.
He describes TRUMP as a low beta bleeding coin with many underwater bagholders, but also points out that liquidity is so thick that volatility has decreased.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43390075/department-of-government-efficiency-meme-coin-plummets-30-as-attention-pivots-to-trump">Department Of Government Efficiency Meme Coin Plummets 30% As Attention Pivots To TRUMP</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$TRUMP

TRUMP Meme Coin Down 42% In A Week: How Low Can It Go?

Rosenblatt analyst Kevin Cassidy maintains Synaptics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNA#NASDAQ">SYNA</a>) with a Buy and maintains $92 price target.

SYNA

Rosenblatt Maintains Buy on Synaptics, Maintains $92 Price Target

Financing

ACON

Aclarion Secures Funding For Its CLARITY Trial For Nociscan

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) with a Outperform and lowers the price target from $318 to $294.

Keefe, Bruyette & Woods Maintains Outperform on RenaissanceRe Holdings, Lowers Price Target to $294

Rosenblatt analyst Mike Genovese maintains Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) with a Buy and raises the price target from $280 to $285.

Rosenblatt Maintains Buy on Fabrinet, Raises Price Target to $285

Rosenblatt analyst Kevin Cassidy maintains Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) with a Buy and raises the price target from $85 to $92.

RMBS

Rosenblatt Maintains Buy on Rambus, Raises Price Target to $92

Baird analyst Eric Coldwell maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Neutral and lowers the price target from $15 to $14.

Baird Maintains Neutral on Owens & Minor, Lowers Price Target to $14

Additionally, the Company expects its financial performance for each of the remaining measures that it previously issued guidance for to be at or above the high-end of the previously announced ranges.

Guidance

GETY

Getty Images Expects Q4 Revenue Of $244M - $250M (Est $244.99M), Revises 2024 Revenue Outlook From $934M - $943M To $936M - $942M (Est $937.01M)

Coloplast (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLPBY#OTC">CLPBY</a>) FY25 Reported Revenue growth expected to be 8-9% YoY from DKK 27,030M

CLPBY

Coloplast FY25 Reported Revenue growth expected to be 8-9% YoY from DKK 27,030M

Telsey Advisory Group analyst Dana Telsey maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Outperform and maintains $265 price target.

Telsey Advisory Group Maintains Outperform on Ralph Lauren, Maintains $265 Price Target

Mizuho analyst Matthew Broome maintains Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) with a Underperform and raises the price target from $44 to $80.

Mizuho Maintains Underperform on Palantir Technologies, Raises Price Target to $80

TransDigm Reaffirms FY25 Sales Outlook Of $8.75B - $8.95B Vs. $8.9B Est; EBITDA Of $4.615B - $4.755B.

Barclays analyst Richard Hightower maintains Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) with a Underweight and lowers the price target from $76 to $74.

Barclays Maintains Underweight on Agree Realty, Lowers Price Target to $74

Applied Therapeutics appoints Johnson as Executive Chairman, CEO steps down

The latest announcement is out from Applied Therapeutics ( ($APLT) ). Applied Therapeutics, Inc. has appointed John H. Johnson as Executive Chairma...

Applied Therapeutics Faces Leadership Changes and Regulatory Hurdles

RBC Capital analyst Brian Abrahams lowered the firm's price target on Applied Therapeutics (APLT) to $1.50 from $4 and keeps a Sector Perform ratin...

Applied Therapeutics price target lowered to $1.50 from $4 at RBC Capital

Applied Therapeutics (APLT – Research Report) received a Hold rating and price target from William Blair analyst Sami Corwin today. The company's s...

William Blair downgrades Applied Therapeutics (APLT) to a Hold

William Blair downgraded Applied Therapeutics (APLT) to Market Perform from Outperform. Published first on TheFly – the ultimate source for real-ti...

Applied Therapeutics downgraded to Market Perform from Outperform at William Blair

William Blair downgraded Applied Therapeutics (APLT) to Market Perform from Outperform without a price target While the management turnover "was a ...

William Blair downgrades Applied Therapeutics on revenue uncertainty

Check out this morning's top movers from around Wall Street, compiled by The Fly.&nbsp; HIGHER – Despegar.com&nbsp;(DESP) up 33% after Prosus annou...

Morning Movers: Despegar surges following deal to be acquired by Prosus

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Members of the Nordstrom family ...

Nordstrom family to take chain private: Morning Buzz

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oruka Therapeutics (ORKA – Research Report), Vertex ...

Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)

ACRS

APLT

AVXL

DESP

ENGN

EXEL

GCMG

HNDAF

IIPR

LAES

MEOBF

MESO

MSTR

NSANF

NSANY

ORKA

PLYA

PONY

RGTI

SMTI

VRTX

VVOS

WULF

XELB

Legal

Press Releases

Kessler Topaz Meltzer & Check, LLP - APLT Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Applied Therapeutics, Inc. (APLT)

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLT

Applied Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - APLT

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Applied Therapeutics, Inc.(APLT) Shareholders

Deadline Alert: Applied Therapeutics, Inc. (APLT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Applied Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; February 18, 2025 Deadline to file Lead Plaintiff Motion

Applied Therapeutics, Inc. (APLT) Investors: February 18, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

Kirby McInerney LLP Urges Investors in Applied Therapeutics, Inc. (APLT) to Inquire About Their Rights in Class Action Lawsuit

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kaspi, Applied Therapeutics, Cassava, and MGPI and Encourages Investors to Contact the Firm

Comments

Applied Therapeutics

Applied Therapeutics (APLT) 옵션

Applied Therapeutics (NASDAQ:APLT) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌